ReAlta Life Sciences

Norfolk, United States Founded: 2018 • Age: 8 yrs
Therapeutic drugs for acute inflammatory and rare diseases are developed.

About ReAlta Life Sciences

ReAlta Life Sciences is a company based in Norfolk (United States) founded in 2018. It operates as a HealthTech. ReAlta Life Sciences has raised $81.5 million across 4 funding rounds from investors including Marathon Pharma. The company has 19 employees as of December 31, 2021. ReAlta Life Sciences offers products and services including RLS-0071 (pegtarazimod) and EPICC Platform. ReAlta Life Sciences operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics, among others.

  • Headquarter Norfolk, United States
  • Employees 19 as on 31 Dec, 2021
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Realta Life Sciences, Inc.
Operational Areas
Healthcare → Healthcare Products & Supplies
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $81.5 M (USD)

    in 4 rounds

  • Latest Funding Round
    $25 M (USD), Series B

    Dec 18, 2024

  • Investors
  • Employee Count
    19

    as on Dec 31, 2021

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of ReAlta Life Sciences

ReAlta Life Sciences offers a comprehensive portfolio of products and services, including RLS-0071 (pegtarazimod) and EPICC Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Drug developed for rare inflammatory disease treatment purposes.

Platform used for dual-targeting inflammatory response moderation.

People of ReAlta Life Sciences
Headcount 10-50
Employee Profiles 10
Board Members and Advisors 9
Employee Profiles
People
Neel K Krishna
Chief Scientific Officer
People
Dawn Buchanan
Vice President, Head Of Clinical Operations
People
John S. Rickman
Chief Financial Officer
People
Jessica Goss
Research Associate III

Unlock access to complete

Board Members and Advisors
people
Barry Strasnick
Director
people
Samuel Massoni
Scientific Advisor
people
Edward A. Heidt Jr.
Chairman
people
Christine Neikirk
Director

Unlock access to complete

Funding Insights of ReAlta Life Sciences

ReAlta Life Sciences has successfully raised a total of $81.5M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $25 million completed in December 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 4
  • Last Round Series B — $25.0M
  • First Round

    (21 Apr 2020)

  • Investors Count 1
Date Amount Transaction Name Valuation Lead Investors Investors
Dec, 2024 Amount Series B - ReAlta Life Sciences Valuation

investors

Sep, 2023 Amount Series B - ReAlta Life Sciences Valuation

investors

Apr, 2021 Amount Series A - ReAlta Life Sciences Valuation Marathon Pharma
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in ReAlta Life Sciences

ReAlta Life Sciences has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Marathon Pharma. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Investor Description Founded Year Domain Location
New treatments for rare neurological and movement disorders are developed.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by ReAlta Life Sciences

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - ReAlta Life Sciences

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Realta Life Sciences Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of ReAlta Life Sciences

ReAlta Life Sciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
mRNA-based therapeutics for diseases including cancer and infections are developed.
domain founded_year HQ Location
Therapeutics for genetic diseases are developed through targeted interventions.
domain founded_year HQ Location
Gene therapies for rare diseases including retinal dystrophies are developed.
domain founded_year HQ Location
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
domain founded_year HQ Location
Developer of drugs for treating rare and autoimmune diseases
domain founded_year HQ Location
Small molecule drugs for rare diseases are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Realta Life Sciences

Frequently Asked Questions about ReAlta Life Sciences

When was ReAlta Life Sciences founded?

ReAlta Life Sciences was founded in 2018 and raised its 1st funding round 2 years after it was founded.

Where is ReAlta Life Sciences located?

ReAlta Life Sciences is headquartered in Norfolk, United States. It is registered at Norfolk, Virginia, United States.

Who is the current CEO of ReAlta Life Sciences?

Ulrich Thienel is the current CEO of ReAlta Life Sciences.

Is ReAlta Life Sciences a funded company?

ReAlta Life Sciences is a funded company, having raised a total of $81.5M across 4 funding rounds to date. The company's 1st funding round was a Series A of $20M, raised on Apr 21, 2020.

How many employees does ReAlta Life Sciences have?

As of Dec 31, 2021, the latest employee count at ReAlta Life Sciences is 19.

What does ReAlta Life Sciences do?

ReAlta Life Sciences, a clinical-stage company, is dedicated to addressing rare diseases through innovative drug development. The company has created a novel class of drugs utilizing the EPICC platform, which offers dual-targeting therapeutic capabilities to rebalance complement and inflammatory processes. Research and development initiatives are centered on acute inflammatory and rare diseases such as Hypoxic Ischemic Encephalopathy, Acute Exacerbations of COPD, Graft-versus-Host Disease, and Platelet Refractoriness. Solutions are developed to modify disease progression by moderating robust components of humoral and cellular inflammatory responses across various therapeutic areas.

Who are the top competitors of ReAlta Life Sciences?

ReAlta Life Sciences's top competitors include Moderna, Spark Therapeutics and BridgeBio.

What products or services does ReAlta Life Sciences offer?

ReAlta Life Sciences offers RLS-0071 (pegtarazimod) and EPICC Platform.

Who are ReAlta Life Sciences's investors?

ReAlta Life Sciences has 1 investor. Key investors include Marathon Pharma.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available